Month: January 2023

Leqembi (lecanemab-irmb), a medication for treating Alzheimer’s, received approval from the U.S. Food and Drug Administration via the Accelerated Approval pathway on January 6th, 2023. Leqembi is the second drug in a newly approved class for Alzheimer’s that addresses the illness’s basic pathophysiology. These drugs are a significant step forward in the ongoing endeavor to … Continue reading "FDA has Granted Accelerated Approval for Leqembi"

According to researchers, the artificial intelligence that powers the chatbot program ChatGPT—famous for its capacity to produce human-like responses when instructed—could aid in the early detection of Alzheimer’s. Recent research from Drexel University’s School of Biomedical Engineering, Science, and Health Systems has revealed that the GPT-3 program from OpenAI can recognize cues from spontaneous speech … Continue reading "Can the AI Driving ChatGPT Aid in the Early Detection of Alzheimer’s?"

The prevalence of neurodegenerative conditions like Alzheimer’s disease rises as the population ages. Proteinopathies, abnormal protein buildups in the brain that impede neuronal function, distinguish these disorders. For instance, the accumulation of beta-amyloid and tau proteins is responsible for Alzheimer’s. Trying to lessen amyloid-beta peptide and tau protein aggregation in neurons is the most extensively … Continue reading "What Causes Insulin Resistance in An Alzheimer’s Patient’s Brain?"